Group 1 - Goldman Sachs reiterated a "Buy" rating for Eli Lilly (LLY.US) and raised the target price from $114.5 billion to $126 billion, reflecting confidence in the obesity drug market despite increasing pricing pressures [1] - Eli Lilly's 2026 revenue guidance indicates approximately 25% year-over-year growth, with expected revenues between $80 billion and $83 billion, significantly above market expectations of $77.62 billion [2] - The company reported Q4 2025 revenues of $19.3 billion, exceeding market expectations of $17.96 billion, with earnings per share of $7.54, also above the expected $6.67 [1] Group 2 - Eli Lilly's management indicated that the upcoming oral obesity drug orforglipron, set to launch in Q2 2026, is expected to have limited substitution effects on existing injectable therapies, supporting further market expansion [1] - The company anticipates earnings per share for 2026 to be between $33.50 and $35.00, with even the lower end exceeding market expectations of $33.23 [2] - The growth momentum is driven by strong demand for obesity treatment drugs, which appears to be unaffected by significant pricing pressures, indicating a shift in the competitive landscape shaped more by consumer demand than insurance coverage [2]